RESEARCH MONOGRAPH · KDC-MN-330

JZL184

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 2 min read

Our opinion on this compound

68/100

First-generation MAGL inhibitor, opened the field, has off-target issues that complicate interpretation

JZL184 is the Cravatt-lab compound that essentially established that you could pharmacologically inhibit MAGL in vivo and see 2-AG-mediated cannabinoid effects. The 2009 Nature Chemical Biology paper is one of the cleaner activity-based protein profiling validations of a target hypothesis you'll find.

Mechanism: irreversible MAGL inhibitor, low-nM IC50, brain-penetrant after IP or oral dosing, produces 8-10x elevations in brain 2-AG. The in vivo phenotype is more THC-like than FAAH inhibition (which makes sense because 2-AG is a higher-efficacy full agonist at CB1) including cataleptic effects at high doses, antinociception, and significant CB1-dependent behavioral changes.

The selectivity issue is the major caveat with JZL184 specifically. At doses needed to fully inhibit MAGL, JZL184 also inhibits FAAH partially (10-30% inhibition typically), which confounds interpretation if you care about discriminating 2-AG from anandamide effects. Long-Cravatt's later compounds (KML29 in particular) were designed specifically to address this and offer cleaner selectivity.

There's also a chronic MAGL-inhibition desensitization issue that Schlosburg, Cravatt, and Lichtman documented: prolonged inhibition leads to CB1 receptor downregulation and tolerance to the cannabinoid phenotype. Thats a real biological finding (sustained 2-AG signaling drives receptor adaptation) but it complicates any chronic in vivo study design.

For research JZL184 is still useful for acute or sub-chronic experiments, especially when paired with a FAAH inhibitor for combined endocannabinoid amplification. Its the workhorse compound in a lot of the early endocannabinoid-pathway pain and inflammation work. Niphakis and Long have nice reviews on the broader MAGL-inhibitor pharmacology if you want context.

Sourcing: research-grade JZL184 is available from multiple suppliers, the carbamate chemistry needs HPLC verification because degradant profile matters. Cost is moderate, less expensive than KML29 typically.

What we like: foundational MAGL tool, well-characterized in vivo phenotype, useful for endocannabinoid amplification studies, paired well with FAAH inhibitors.

What we dont like: FAAH cross-reactivity at high doses, chronic-dosing tolerance issue, somewhat dirty for modern selectivity standards.

Solid first-generation tool. We'd reach for KML29 first now for any new work where the selectivity matters.

Evidence: 65
Mechanism: 78
Reliability: 70
Safety: 65
Sourcing: 78
Value: 70
Signal: 60
Staying power: 60

Plain-language summary Intrigue 50 / 100

JZL184 is the canonical research probe for blocking MAGL, the enzyme that breaks down the endocannabinoid 2-AG. It was developed in the Cravatt laboratory at Scripps and works by permanently inactivating the enzyme, which raises 2-AG levels and produces cannabinoid-like effects without direct receptor agonism. Animal work shows analgesic and anti-inflammatory activity, but a meaningful complication is that JZL184 also partially inhibits FAAH (about 300-fold MAGL preference), muddying interpretation of some early studies. Cleaner second-generation tools like KML29 have largely replaced it for definitive mechanism work. Not a clinical compound. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Selective MAGL inhibitor (research)

A covalent inhibitor of monoacylglycerol lipase (MAGL); the canonical research probe for elevating endogenous 2-AG.

Abstract

JZL184 (CAS 1101854-58-3; molecular formula C27H24F2N2O5; molecular weight 510.49) is a covalent piperidinyl-carbamate inhibitor of monoacylglycerol lipase (MAGL) developed by Cravatt and colleagues at Scripps. The compound carbamoylates the active-site serine of MAGL, producing irreversible enzyme inactivation. Selective for MAGL over FAAH (approximately 300-fold) and other serine hydrolases. Pharmacological consequence: elevation of endogenous 2-AG (the principal full-agonist endocannabinoid) without direct CB receptor agonism. Behavioral effects are more THC-like than FAAH inhibition (anxiolysis, analgesia, hypothermia, catalepsy at high dose), reflecting the higher tonic CB1 occupancy from elevated 2-AG. Used as the canonical MAGL inhibitor in academic neuroscience for studies of 2-AG signaling and CB1-mediated synaptic plasticity. No human clinical development.

Mechanism of action

Covalent carbamate MAGL inhibitor; irreversible inactivation. Approximately 300-fold selective for MAGL over FAAH. Elevates endogenous 2-AG.

Reported research dose ranges

Rodent research 4 to 40 mg/kg intraperitoneal.

References

Long JZ, et al. Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects. Nat Chem Biol 2009.
Long JZ, et al. Dual blockade of FAAH and MAGL identifies behavioral processes regulated by endocannabinoid crosstalk in vivo. Proc Natl Acad Sci 2009.
Mulvihill MM, Nomura DK. Therapeutic potential of monoacylglycerol lipase inhibitors. Life Sci 2013.

Read the full monograph

The full reference document is available as a research-use-only PDF download. Note: PDFs for newly added compounds may take a few hours to propagate after this article was published.

KDC-MN-330

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

JZL184

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs